Efficacy/Safety of Lefamulin in Severe Community-Acquired Bacterial Pneumonia
Pooled data from the LEAP 1 and 2 trials were used to study the efficacy and safety of lefamulin in patients with CABP at risk for severe pneumonia.
Pooled data from the LEAP 1 and 2 trials were used to study the efficacy and safety of lefamulin in patients with CABP at risk for severe pneumonia.
High hospital-level bronchodilator use not associated with better outcomes; adjustment follows AAP recommendations to limit routine use for bronchiolitis
Asthma and chronic obstructive pulmonary disease (COPD) do not appear to increase the risk of mortality in patients with COVID-19.
Use of vasoactive intestinal peptide to treat critical COVID-19 respiratory failure in patients with comorbidities has shown promise.
Expired or previously used and sterilized N95 respirators can be used when new N95 respirators are unavailable during the COVID-19 pandemic.
In patients who were hospitalized with severe coronavirus disease, treatment with lopinavir-ritonavir did not provide a substantial benefit beyond standard care.
Patients with established chronic lung allograft dysfunction may have a higher risk for respiratory syncytial virus infections, but lung function decline does not appear to be significantly affected.